BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mok MY, Shoenfeld Y. Recent advances and current state of immunotherapy in systemic lupus erythematosus. Expert Opin Biol Ther 2016;16:927-39. [PMID: 27032059 DOI: 10.1517/14712598.2016.1171840] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Bolouri N, Akhtari M, Farhadi E, Mansouri R, Faezi ST, Jamshidi A, Mahmoudi M. Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus. Inflamm Res 2022. [PMID: 35298669 DOI: 10.1007/s00011-022-01554-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Basiri A, Pazhouhnia Z, Beheshtizadeh N, Hoseinpour M, Saghazadeh A, Rezaei N. Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises. Stem Cell Rev Rep 2021;17:163-75. [PMID: 32564256 DOI: 10.1007/s12015-020-09994-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 35.0] [Reference Citation Analysis]
3 Patel M, Chen J, Kim S, Garg S, Flannery B, Haddadin Z, Rankin D, Halasa N, Talbot HK, Reed C. Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States. Emerg Infect Dis 2020;26:1720-30. [PMID: 32348234 DOI: 10.3201/eid2608.191493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
4 Borba VV, Zandman-Goddard G, Shoenfeld Y. Prolactin and autoimmunity: The hormone as an inflammatory cytokine. Best Pract Res Clin Endocrinol Metab 2019;33:101324. [PMID: 31564625 DOI: 10.1016/j.beem.2019.101324] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
5 Kim CJ, Lee CG, Jung JY, Ghosh A, Hasan SN, Hwang SM, Kang H, Lee C, Kim GC, Rudra D, Suh CH, Im SH. The Transcription Factor Ets1 Suppresses T Follicular Helper Type 2 Cell Differentiation to Halt the Onset of Systemic Lupus Erythematosus. Immunity 2018;49:1034-1048.e8. [PMID: 30566881 DOI: 10.1016/j.immuni.2018.10.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 11.3] [Reference Citation Analysis]
6 Pradhan V, Pandit P, Surve P, Lecerf M, Rajadhyaksha A, Nadkar M, Khadilkar PV, Chougule DA, Naigaonkar AA, Lacroix-Desmazes S, Bayry J, Ghosh K, Kaveri SV. Catalytic antibodies in patients with systemic lupus erythematosus. Eur J Rheumatol 2018;5:173-8. [PMID: 30185370 DOI: 10.5152/eurjrheum.2018.17194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Hruskova Z, Tesar V. Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. Expert Opin Biol Ther 2018;18:989-96. [PMID: 30040494 DOI: 10.1080/14712598.2018.1504918] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Li W, Sivakumar R, Titov AA, Choi SC, Morel L. Metabolic Factors that Contribute to Lupus Pathogenesis. Crit Rev Immunol 2016;36:75-98. [PMID: 27480903 DOI: 10.1615/CritRevImmunol.2016017164] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]